Prothena | PRTA - Selling And Administration Expenses

Stock Price
10.75
Daily Change
0.02 0.19%
Monthly
15.47%
Yearly
10.82%
Q2 Forecast
10.43

Prothena reported $7.65M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Prothena USD 7.65M 5.59M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024